Home LiteratureArticle Details
PMID: 15555995 Published · ppublish English Comment Journal Article

Targeting alpha-synuclein in Parkinson's disease.

Chemistry & biology ·Vol. 11 ·No. 11 ·2004-11-00 ·Pages 1476-8

Kapurniotu A

Abstract

alpha-Synuclein aggregation into fibrils is associated with the pathogenesis of Parkinson's disease (PD). Li et al. provide strong evidence that rifampicin interacts with alpha-synuclein and inhibits its fibrillization. Rifampicin could be a promising candidate for therapeutic application for PD.

MeSH Terms
Drug Delivery Systems Humans Nerve Tissue Proteins/antagonists & inhibitors,metabolism Parkinson Disease/drug therapy Rifampin/metabolism,therapeutic use Synucleins alpha-Synuclein
Chemicals
Nerve Tissue Proteins SNCA protein, human Synucleins alpha-Synuclein Rifampin
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Kapurniotu Aphrodite
Laboratory of Bioorganic and Medicinal Chemistry, Institute of Biochemistry, University Hospital of the RWTH Aachen, Pauwelstrasse 30, D-52074 Aachen, Germany.
Article Info
Journal
Chemistry & biology
Abbr.
Chem Biol
ISSN
1074-5521
DOI
10.1016/j.chembiol.2004.11.003
Published
2004-11-00
Pages
1476-8
Language
English
Region
United States
NLM ID
9500160
Subset
IM
Corrections
CommentOn
PMID: 15556002
External Links
PubMed source DOI: 10.1016/j.chembiol.2004.11.003 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2